Science and Research

Canopy 1 / CACZ885U2301

Efficacy and safety of Pembrolizumab plus platinum-based chemotherapy with or without Canakinumab as first line therapy for locally advanced or metastatic NSCLC. Phase III, Randomized, double blind, placebo controlled

Study details
Study-ID: NCT03631199, 2018-001547-32
Study-ID: NCT03631199, 2018-001547-32
DZL Disease Area: LC
DZL Disease Area: LC
Study Type: Interventional
Study Type: Interventional
DZL Role: DZL recruiting center
DZL Role: DZL recruiting center
Funding: Externally - industry
Funding: Externally - industry
DZL Participating Sites: CPC-M
DZL Participating Sites: CPC-M
Start Date: 21.12.2018
Completion Date: 07.06.2027
Status: Closed
Status: Closed
DZL recruiting center
Link to Study


close
chevron-down

Unsere Seite verwendet Cookies und ähnliche Technologien. Mit der Nutzung der Webseite stimmen Sie der Verwendung von Cookies zu. Mehr Informationen dazu finden Sie in unserer Datenschutzerklärung.